Scarica l'app Stockscreener
7.13
0.42%
0.03
Dopo l'orario di chiusura:
7.13
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IBRX Giù?
Forum
Previsione
Precedente Chiudi:
$7.10
Aprire:
$7.25
Volume 24 ore:
8.07M
Relative Volume:
0.48
Capitalizzazione di mercato:
$7.47B
Reddito:
$140.98M
Utile/perdita netta:
$-854.60M
Rapporto P/E:
-8.3489
EPS:
-0.854
Flusso di cassa netto:
$-299.31M
1 W Prestazione:
-0.56%
1M Prestazione:
-10.54%
6M Prestazione:
+221.17%
1 anno Prestazione:
+132.25%
Intervallo 1D:
$7.05
$7.34
Intervallo di 1 settimana:
$6.9167
$7.44
Portata 52W:
$1.95
$12.43
Immunitybio Inc Stock (IBRX) Company Profile
Nome
Immunitybio Inc
Settore
Industria
Telefono
(844) 696-5235
Indirizzo
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
7.13 | 7.44B | 140.98M | -854.60M | -299.31M | -0.854 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-12 | Ripresa | BTIG Research | Buy |
| 2025-05-20 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-03-06 | Iniziato | H.C. Wainwright | Buy |
| 2025-01-10 | Iniziato | BTIG Research | Buy |
| 2023-05-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-08-03 | Iniziato | Jefferies | Buy |
Mostra tutto
Immunitybio Inc Borsa (IBRX) Ultime notizie
ImmunityBio Founder Pushes Back After FDA Warning Letter Over Anktiva Claims — Says Ad 'Never Aired At All' - Stocktwits
ImmunityBio, Inc. (IMMP) Investigation: Bronstein, Gewirtz & Gros - The National Law Review
IBRX Stock Climbs Overnight: ImmunityBio Declares ‘All Systems Go’ For Dunkirk Anktiva Manufacturing Push - Stocktwits
IBRX Founder’s ‘Congrats’ To GSK Sparks Debate After FDA Fast Drug Approvals — Retail Slams Big Pharma Bias Over Anktiva - Stocktwits
ImmunityBio, Inc. (NASDAQ:IBRX): Are Analysts Optimistic? - Moomoo
Bronstein, Gewirtz & Grossman, LLC Is Investigating ImmunityBio, Inc. (IMMP) And Encourages Investors to Connect - ACCESS Newswire
IBRX stock eyes best week since February: Founder highlights new Anktiva-NK cell therapy study - MSN
ImmunityBio | 4: Statement of changes in beneficial ownership of securities-Director Selecky Christobel - Moomoo
ImmunityBio (IBRX): One of the Best Performing Growth Stocks So Far in 2026 - Insider Monkey
ImmunityBio (IBRX) director awarded 65,600 stock options at $7.25 strike - Stock Titan
ImmunityBio (IBRX) director Wesley Clark receives 65,600 stock options at $7.25 strike - Stock Titan
ImmunityBio (IBRX) director granted 65,600 stock options at $7.25 strike - Stock Titan
Director at ImmunityBio (NASDAQ: IBRX) awarded 65,600 options - Stock Titan
ImmunityBio (IBRX) re-elects full board, ratifies Deloitte as 2026 auditor - Stock Titan
2026-06-09 | Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc. (IMMP) Stockholders to Inquire about Securities Investigation | NDAQ:IMMP | Press Release - Stockhouse
IBRX Stock Set To Snap 2 Weeks In Red: Anktiva Joins Global Blockbusters On Macau Drug List - Stocktwits
FDA to Review Expanded Use of Cancer Drug - Los Angeles Business Journal
IBRX Stock Eyes Green Open Ahead Of Earnings — What Happened With Anktiva Over The Weekend - Stocktwits
IBRX Stock Still A Buy After Worst Day In Over A Year? Why This Analyst Is Shrugging Off FDA Warning Letter - Stocktwits
ImmunityBio, Inc. (IMMP) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
ImmunityBio, Inc.: Shareholders Board Members Managers and Company Profile | US45256X1037 - marketscreener.com
ImmunityBio Inc Cash Flow – XETR:26CA - TradingView
ImmunityBio director Simon Barry J. sells $165,305 in stock - Investing.com UK
Director Barry Simon Sells 23,033 Shares of ImmunityBio Inc (IBR - GuruFocus
Immunitybio earnings loom amid Anktiva growth, FDA scrutiny - Investing.com
ImmunityBio Inc. (IBRX): One of the Most Shorted Mid-Cap Stocks to Buy Now - Yahoo Finance
ImmunityBio director Simon Barry J. sells $165,305 in stock By Investing.com - Investing.com India
ImmunityBio (IBRX) director Simon sells 23,033 shares under Rule 10b5-1 plan - Stock Titan
IBRX Vs IOVA: Which Cancer Immunotherapy Stock Has Bigger Breakout Ahead? - Stocktwits
IBRX Stock Rally Not Over Yet? Chairman Says Trump Diplomacy Led To ‘Amazing Results’ For Cancer Drug - Stocktwits
IBRX Stock Set To Snap 2 Days Of Losses? Anktiva Back In Focus Ahead Of COVID-Cancer Link Data - Stocktwits
ImmunityBio responds to FDA promotional compliance concerns - Investing.com
ImmunityBio stock rises after FDA compliance response - Investing.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
ImmunityBio Advances HPV-Positive Head and Neck Cancer Trial, Setting Up a New Catalyst for IBRX Investors - TipRanks
IBRX: ANKTIVA delivers durable cancer responses, drives global growth, and expands into new indications - TradingView
[144] ImmunityBio, Inc. SEC Filing - Stock Titan
ImmunityBio secures five US patents for Anktiva in bladder cancer - MSN
ImmunityBio ASCO ANKTIVA Data Reframes Lung And Bladder Cancer Outlook - Yahoo Finance
D Boral Capital maintains ImmunityBio (IBRX) buy recommendation - MSN
ImmunityBio Inc stock (US45258J1025): HC Wainwright reiteration follows Nasdaq pullback - AD HOC NEWS
Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc. (IMMP) Investors to Inquire about Securities Investigation - ACCESS Newswire
IBRX Reiterates by HC Wainwright -- Price Target Maintained at $15 - GuruFocus
H.C. Wainwright Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $15 - Moomoo
IBRX Stock Price, Quote & Chart | IMMUNITYBIO INC (NASDAQ:IBRX) - ChartMill
ImmunityBio (IBIO) Showcases Promising Clinical Data for ANKTIVA at ASCO 2026 - GuruFocus
ImmunityBio presents ANKTIVA data at ASCO meeting By Investing.com - Investing.com Nigeria
ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026 - The AI Journal
ImmunityBio presents ANKTIVA data at ASCO meeting - Investing.com
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm - Eastern Progress
Immunitybio Inc Azioni (IBRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.40%
0.29%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):